Thursday, 31 December 2009

Penethamate Hydriodide




In some countries, this medicine may only be approved for veterinary use.

Scheme

BAN

CAS registry number (Chemical Abstracts Service)

0000808-71-9

Chemical Formula

C22-H32-I-N3-O4-S

Molecular Weight

561

Therapeutic Category

Antibacterial: Penicillin, penicillinase-sensitive

Chemical Name

(2-Diethylaminoethyl) [3S,6R,7R)-2,2-dimethyl-6-(2-phenylacetamido)penam-3-carboxylat]-hydroiodid

Foreign Name

  • Penethacillin hydroiodid (German)

Generic Names

  • Pénéthacilline (OS: DCF)
  • Penethamate Hydriodide (OS: BANM)
  • Bronchopon (IS)

Brand Names

  • Benestermycin (Penethamate Hydriodide and Benzylpenicillin benethamin, Framycetin (veterinary use))
    Boehringer Ingelheim, Sweden; Boehrvet, Germany


  • Ingel-Mamyzin (veterinary use)
    Boehringer Ingelheim Vetmedica, Austria; Boehrvet, Germany


  • Juvanesta Comp (Penethamate Hydriodide and Benzylpenicillin, + Dihydrostreptomycin (veterinary use))
    Boehringer Ingelheim Vet, Norway


  • Leocillin M (Penethamate Hydriodide and Dihydrostreptomycin (veterinary use))
    Boehringer Ingelheim Vet, Norway


  • Leocillin (veterinary use)
    Boehringer Ingelheim Vet, Norway


  • Mammyzine (veterinary use)
    Boehringer Ingelheim Animal, Belgium


  • Mamyzin (veterinary use)
    Boehringer Ingelheim, Australia; Boehringer Ingelheim, Sweden; Boehringer Ingelheim Animal, Netherlands; Boehringer Ingelheim Animals, New Zealand; Boehringer Ingelheim vet, Switzerland; Boehringer Ingelheim vet, Italy; Vetcare, Finland


  • Mastinject (veterinary use)
    Bomac Animal Health, Australia; Serumber, Germany


  • Penetavet (veterinary use)
    Boehringer Ingelheim Santé Animale, France


  • Penethaject (veterinary use)
    Bomac, New Zealand


  • Stop M (veterinary use)
    Boehringer Ingelheim Santé Animale, France


  • Ubro Yellow (Penethamate Hydriodide and Dihydrostreptomycin, + Framycetin, + Prednisolone (veterinary use))
    Boehringer Ingelheim Animals, New Zealand; Boehringer Ingelheim Vetmedica, Austria


  • Umpimycin Vet (Penethamate Hydriodide and Framycetin, + Benzylpenicillin (veterinary use))
    Vetcare, Finland

International Drug Name Search

Glossary

BANBritish Approved Name
BANMBritish Approved Name (Modified)
DCFDénomination Commune Française
ISInofficial Synonym
OSOfficial Synonym

Click for further information on drug naming conventions and International Nonproprietary Names.

Monday, 21 December 2009

Nifelong




Nifelong may be available in the countries listed below.


Ingredient matches for Nifelong



Nifedipine

Nifedipine is reported as an ingredient of Nifelong in the following countries:


  • Myanmar

International Drug Name Search

Saturday, 19 December 2009

Digitalis Glycoside Toxicity Medications


Drugs associated with Digitalis Glycoside Toxicity

The following drugs and medications are in some way related to, or used in the treatment of Digitalis Glycoside Toxicity. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

Learn more about Digitalis Glycoside Toxicity





Drug List:

Friday, 27 November 2009

Prinivil Plus




Prinivil Plus may be available in the countries listed below.


Ingredient matches for Prinivil Plus



Hydrochlorothiazide

Hydrochlorothiazide is reported as an ingredient of Prinivil Plus in the following countries:


  • Spain

Lisinopril

Lisinopril dihydrate (a derivative of Lisinopril) is reported as an ingredient of Prinivil Plus in the following countries:


  • Spain

International Drug Name Search

Sunday, 15 November 2009

Ubilon




Ubilon may be available in the countries listed below.


Ingredient matches for Ubilon



Tibolone

Tibolone is reported as an ingredient of Ubilon in the following countries:


  • Bangladesh

International Drug Name Search

Friday, 13 November 2009

Disflatyl




Disflatyl may be available in the countries listed below.


Ingredient matches for Disflatyl



Dimeticone

Dimeticone is reported as an ingredient of Disflatyl in the following countries:


  • Finland

  • Indonesia

Simeticone

Simeticone is reported as an ingredient of Disflatyl in the following countries:


  • Bahrain

  • Cyprus

  • Egypt

  • Finland

  • Georgia

  • Jordan

  • Kuwait

  • Lebanon

  • Oman

  • Philippines

  • Poland

  • Qatar

  • Russian Federation

  • Saudi Arabia

  • Singapore

  • Sudan

  • Switzerland

  • Thailand

  • United Arab Emirates

  • Yemen

International Drug Name Search

Friday, 6 November 2009

Tanvimil E




Tanvimil E may be available in the countries listed below.


Ingredient matches for Tanvimil E



Tocopherol, α-

Tocopherol, α- acetate (a derivative of Tocopherol, α-) is reported as an ingredient of Tanvimil E in the following countries:


  • Argentina

International Drug Name Search

Tuesday, 20 October 2009

Tiamina Clorhidrato L.CH.




Tiamina Clorhidrato L.CH. may be available in the countries listed below.


Ingredient matches for Tiamina Clorhidrato L.CH.



Thiamine

Thiamine hydrochloride (a derivative of Thiamine) is reported as an ingredient of Tiamina Clorhidrato L.CH. in the following countries:


  • Chile

International Drug Name Search

Monday, 12 October 2009

Neurolal




Neurolal may be available in the countries listed below.


Ingredient matches for Neurolal



Phenobarbital

Phenobarbital is reported as an ingredient of Neurolal in the following countries:


  • Algeria

International Drug Name Search

Pyrantelum




Pyrantelum may be available in the countries listed below.


Ingredient matches for Pyrantelum



Pyrantel

Pyrantel embonate (a derivative of Pyrantel) is reported as an ingredient of Pyrantelum in the following countries:


  • Latvia

  • Poland

International Drug Name Search

Sunday, 11 October 2009

Ciclopentolato Poen




Ciclopentolato Poen may be available in the countries listed below.


Ingredient matches for Ciclopentolato Poen



Cyclopentolate

Cyclopentolate hydrochloride (a derivative of Cyclopentolate) is reported as an ingredient of Ciclopentolato Poen in the following countries:


  • Argentina

International Drug Name Search

Monday, 5 October 2009

Docusate Sodium




Dosage Form: capsule, liquid filled
Docusate Sodium 100 mg

DRUG FACTS



ACTIVE INGREDIENT (IN EACH CAPSULE)


Docusate Sodium 100 mg



PURPOSE


Stool softener



USES


  • relieves occasional constipation (irregularity)

    generally produces a bowel movement in 12 to 72 hours




Warnings



Do not use


  • if you are presently taking mineral oil, unless told to do so by a doctor


Ask a doctor before use if you have


  • stomach pain

  • nausea

  • vomiting

  • noticed a sudden change in bowel movements that continues over a period of 2 weeks


Stop use and ask a doctor if


  • you have rectal bleeding or fail to have a bowel movement after use of a laxative.

    These could be signs of a serious condition.

  • you need to use a stool softener laxative for more than 1 week


If pregnant or breast-feeding,


ask a health professional before use.



Keep out of reach of children.


In case of overdose, get medical help or contact a Poison Control Center right away.



DIRECTIONS


  • Take only by mouth. Doses may be taken as a single daily dose or in divided doses.








  • adults and children

    12 years and over
    take 1-3

    capsules daily
    children 2 to under

    12 years of age
    take 1

    capsules daily
    children under 2 yearsask a doctor


OTHER INFORMATION


  • each capsule contains: sodium 6 mg

  • store at 25°C (77°F)); excursions permitted between 15°-30°C (59°-86°F)


INACTIVE INGREDIENTS


FD&C Red No. 40, FD&C Yellow No. 6, edible ink, gelatin, glycerin, polyethylene blycol, propylene glycol, purified water and sorbitol special



QUESTIONS OR COMMENTS?


Distributed by: Major Pharmaceuticals, 31778 Enterprise Drive, Livonia, MI 48150, U.S.A.


call toll free 734-743-6000


Repackaged by:


Contract Pharmacy Services-PA

125 Titus Ave Suite 200

Warrington, PA 18976 USA


Original--07/2010--NJW



Package Label


Blister of 60 Capsules










Docusate Sodium 
Docusate Sodium  capsule, liquid filled










Product Information
Product TypeHUMAN OTC DRUGNDC Product Code (Source)67046-139 (0904-7889)
Route of AdministrationORALDEA Schedule    








Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
Docusate Sodium (DOCUSATE)Docusate Sodium100 mg





Inactive Ingredients
Ingredient NameStrength
No Inactive Ingredients Found


















Product Characteristics
ColorRED (Transparent red)Scoreno score
ShapeCAPSULE (oblong softgel)Size10mm
FlavorImprint CodeP51
Contains      














Packaging
#NDCPackage DescriptionMultilevel Packaging
167046-139-3030 CAPSULE In 1 BLISTER PACKNone
267046-139-6060 CAPSULE In 1 BLISTER PACKNone










Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
OTC monograph not finalpart33407/30/2010


Labeler - Contract Pharmacy Services-PA (945429777)
Revised: 07/2010Contract Pharmacy Services-PA




More Docusate Sodium resources


  • Docusate Sodium Side Effects (in more detail)
  • Docusate Sodium Use in Pregnancy & Breastfeeding
  • Drug Images
  • Docusate Sodium Drug Interactions
  • Docusate Sodium Support Group
  • 6 Reviews for Docusate Sodium - Add your own review/rating


  • Docusate Professional Patient Advice (Wolters Kluwer)

  • Aqualax Concise Consumer Information (Cerner Multum)

  • Calcium Stool Softener Concise Consumer Information (Cerner Multum)

  • Colace MedFacts Consumer Leaflet (Wolters Kluwer)

  • Diocto Liquid MedFacts Consumer Leaflet (Wolters Kluwer)

  • Docusate Salts Monograph (AHFS DI)

  • Dostinex Monograph (AHFS DI)

  • Enemeez Mini Enema MedFacts Consumer Leaflet (Wolters Kluwer)



Compare Docusate Sodium with other medications


  • Constipation

Monday, 21 September 2009

Vigicer




Vigicer may be available in the countries listed below.


Ingredient matches for Vigicer



Modafinil

Modafinil is reported as an ingredient of Vigicer in the following countries:


  • Argentina

International Drug Name Search

Sunday, 20 September 2009

Weifa-Kalsium




Weifa-Kalsium may be available in the countries listed below.


Ingredient matches for Weifa-Kalsium



Calcium Carbonate

Calcium Carbonate is reported as an ingredient of Weifa-Kalsium in the following countries:


  • Norway

International Drug Name Search

Thursday, 17 September 2009

Kejifen




Kejifen may be available in the countries listed below.


Ingredient matches for Kejifen



Serrapeptase

Serrapeptase is reported as an ingredient of Kejifen in the following countries:


  • Japan

International Drug Name Search

Monday, 14 September 2009

Ursolit




Ursolit may be available in the countries listed below.


Ingredient matches for Ursolit



Ursodeoxycholic Acid

Ursodeoxycholic Acid is reported as an ingredient of Ursolit in the following countries:


  • Israel

International Drug Name Search

Tuesday, 8 September 2009

Tussipect




Tussipect may be available in the countries listed below.


Ingredient matches for Tussipect



Dextromethorphan

Dextromethorphan hydrobromide (a derivative of Dextromethorphan) is reported as an ingredient of Tussipect in the following countries:


  • Belgium

  • Luxembourg

International Drug Name Search

Monday, 7 September 2009

Trisomy 18 Medications


There are currently no drugs listed for "Trisomy 18".

Learn more about Trisomy 18





Drug List:

Saturday, 5 September 2009

Triblix




Triblix may be available in the countries listed below.


Ingredient matches for Triblix



Cefalexin

Cefalexin is reported as an ingredient of Triblix in the following countries:


  • Argentina

International Drug Name Search

Monday, 24 August 2009

Cefuro-Puren




Cefuro-Puren may be available in the countries listed below.


Ingredient matches for Cefuro-Puren



Cefuroxime

Cefuroxime axetil (a derivative of Cefuroxime) is reported as an ingredient of Cefuro-Puren in the following countries:


  • Germany

International Drug Name Search

Sunday, 23 August 2009

Azeclear




Azeclear may be available in the countries listed below.


Ingredient matches for Azeclear



Azelaic Acid

Azelaic Acid is reported as an ingredient of Azeclear in the following countries:


  • Oman

International Drug Name Search

Friday, 21 August 2009

Diclofenaco Sandoz




Diclofenaco Sandoz may be available in the countries listed below.


Ingredient matches for Diclofenaco Sandoz



Diclofenac

Diclofenac sodium salt (a derivative of Diclofenac) is reported as an ingredient of Diclofenaco Sandoz in the following countries:


  • Spain

International Drug Name Search

Thursday, 20 August 2009

Buserelin




In some countries, this medicine may only be approved for veterinary use.

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

L02AE01

CAS registry number (Chemical Abstracts Service)

0057982-77-1

Chemical Formula

C60-H86-N16-O13

Molecular Weight

1239

Therapeutic Categories

Antineoplastic agent

Gonadotropin releasing hormone (GnRH) agonist

Chemical Name

Luteinizing hormone-releasing factor (pig), 6-[O-(1,1-dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-10-deglycinamide-

Foreign Names

  • Buserelinum (Latin)
  • Buserelin (German)
  • Buséréline (French)
  • Buserelina (Spanish)

Generic Names

  • Buserelin (OS: BAN)
  • Buserelina (OS: DCIT)
  • Buséréline (OS: DCF)
  • Hoe 766 (IS)
  • S 746766 (IS)
  • Buserelin (PH: BP 2010, Ph. Eur. 6)
  • Buséréline (PH: Ph. Eur. 6)
  • Buserelinum (PH: Ph. Eur. 6)
  • Buserelin Acetate (OS: JAN, USAN, BANM)

Brand Names

  • Receptal (veterinary use)
    Hoechst Roussel Vet, Portugal; Hoechst Vet, Ireland; Intervet, United Kingdom


  • Suprefact
    Aventis, Singapore


  • Bigonist
    Sanofi-Aventis, France


  • Buserecur
    Fuji Yakuhin, Japan


  • Buserelin aniMedica (veterinary use)
    Animedica, Austria; Animedica, Germany; Animedica, Poland


  • Buserol (veterinary use)
    Gräub, Switzerland


  • Busol (veterinary use)
    Laboratoires Biové, France


  • Fuset
    Mylan Pharmaceutical, Japan


  • Itorelin
    ILSIto Life Sciences, Japan


  • Metrelef
    Ferring, Germany


  • Profact
    Sanofi-Aventis, Germany


  • Receptal (veterinary use)
    Intervet, Austria; Intervet, Belgium; Intervet, Germany; Intervet, Finland; Intervet, Italy; Intervet, Netherlands; Intervet, Norway; Intervet, Sweden; Intervet, South Africa; Intervet / Schering-Plough Animal Health, New Zealand; Intervet/Schering-Plough Animal Health, Australia; Veterinaria, Switzerland


  • Réceptal (veterinary use)
    Intervet, France


  • Suprecur
    Sanofi Aventis, Japan; Sanofi-Aventis, Austria; Sanofi-Aventis, Denmark; Sanofi-Aventis, Finland; Sanofi-Aventis, United Kingdom; Sanofi-Aventis, Hong Kong; Sanofi-Aventis, Ireland; Sanofi-Aventis, Norway; Sanofi-Aventis, Sweden; Sanofi-Aventis, Turkey


  • Suprefact Nasal
    Sanofi-Aventis S.A., Spain


  • Suprefact
    Aventis, Israel; Aventis, Iceland; Aventis, Luxembourg; Aventis, Serbia; Aventis, Slovakia; Aventis, South Africa; Dr. Fisher, Netherlands; Euro, Netherlands; Medcor, Netherlands; Sanofi-Aventis, Argentina; Sanofi-Aventis, Austria; Sanofi-Aventis, Belgium; Sanofi-Aventis, Bahrain; Sanofi-Aventis, Canada; Sanofi-Aventis, Denmark; Sanofi-Aventis, Egypt; Sanofi-Aventis, Finland; Sanofi-Aventis, France; Sanofi-Aventis, United Kingdom; Sanofi-Aventis, Greece; Sanofi-Aventis, Hungary; Sanofi-Aventis, Ireland; Sanofi-Aventis, Iraq; Sanofi-Aventis, Iran; Sanofi-Aventis, Italy; Sanofi-Aventis, Kuwait; Sanofi-Aventis, Lebanon; Sanofi-Aventis, Malta; Sanofi-Aventis, Malaysia; Sanofi-Aventis, Netherlands; Sanofi-Aventis, New Zealand; Sanofi-Aventis, Oman; Sanofi-Aventis, Qatar; Sanofi-Aventis, Saudi Arabia; Sanofi-Aventis, Sweden; Sanofi-Aventis, Singapore; Sanofi-Aventis, Syria; Sanofi-Aventis, Thailand; Sanofi-Aventis, Turkey; Sanofi-Aventis, Yemen; Sanofi-Aventis - Produtos farmacêuticos, S.A., Portugal; Sanofi-Aventis S.A., Spain; Sanofi-Synthelabo, United Arab Emirates; Sanofi-Synthelabo, Jordan


  • Suprefact Depot
    Aventis, Brazil; Sanofi-Aventis, Austria; Sanofi-Aventis, Switzerland; Sanofi-Aventis, Hungary; Sanofi-Aventis, Israel; Sanofi-Aventis, Norway; Sanofi-Aventis, Sweden; Sanofi-Aventis - Produtos farmacêuticos, S.A., Portugal; Sanofi-Aventis S.A., Spain


  • Supremon
    Sanofi-Aventis, Taiwan

International Drug Name Search

Glossary

BANBritish Approved Name
BANMBritish Approved Name (Modified)
DCFDénomination Commune Française
DCITDenominazione Comune Italiana
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
PHPharmacopoeia Name
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Tuesday, 18 August 2009

Alfogel




Alfogel may be available in the countries listed below.


Ingredient matches for Alfogel



Aluminium Phosphate

Aluminium Phosphate is reported as an ingredient of Alfogel in the following countries:


  • Serbia

Aluminium Phosphate hydrated (a derivative of Aluminium Phosphate) is reported as an ingredient of Alfogel in the following countries:


  • Serbia

International Drug Name Search

Friday, 14 August 2009

Bi Love G




Bi Love G may be available in the countries listed below.


Ingredient matches for Bi Love G



Riboflavin

Riboflavin tetrabutyrate (a derivative of Riboflavin) is reported as an ingredient of Bi Love G in the following countries:


  • Japan

International Drug Name Search

Saturday, 25 July 2009

rubella virus vaccine


Generic Name: rubella virus vaccine (roo BEL a VYE rus vax EEN)

Brand Names: Meruvax II


What is rubella virus vaccine?

Rubella is a serious disease caused by a virus. It is spread from person to person through the air.


Rubella virus (also called German Measles) causes skin rash, fever, swollen glands, and joint pain. Becoming infected with rubella during pregnancy can result in a miscarriage or serious birth defects.


The rubella virus vaccine is used to help prevent this disease in adults and children who are at least 12 months old.


This vaccine works by exposing you to a small dose of the virus or a protein from the virus, which causes the body to develop immunity to the disease. This vaccine will not treat an active infection that has already developed in the body.


Rubella virus vaccine is for use in children between the ages of 12 months and 6 years old, and in adults who have never received the vaccine or had the diseases.


Although immunization against rubella virus is available in a single vaccine, it may be best for you to receive a combination measles, mumps, and rubella (MMR) vaccine. Follow your doctor's instructions.

Like any vaccine, the rubella virus vaccine may not provide protection from disease in every person.


What is the most important information I should know about this vaccine?


Although immunization against rubella virus is available in a single vaccine, it may be best for you to receive a combination measles, mumps, and rubella (MMR) vaccine. Follow your doctor's instructions. You should not receive a rubella virus vaccine if you are pregnant. Wait until after your child is born to receive the vaccine. Avoid becoming pregnant for at least 3 months after receiving a rubella virus vaccine.

The first rubella virus vaccine is usually given to a child who is 12 to 15 month old. The booster shots are then given between 4 and 6 years of age. A measles, mumps, and rubella (MMR) vaccine should then be given before the child starts elementary school.


Adults born after 1956 should receive at least one measles, mumps, and rubella vaccination if they have never had the diseases or received an MMR vaccine during their lifetime.


Your individual booster schedule may be different from these guidelines. Follow your doctor's instructions or the schedule recommended by the health department of the state you live in.


Be sure you receive all recommended doses of this vaccine. If you do not receive the full series of vaccines, you may not be fully protected against the disease.


You can still receive a vaccine if you have a minor cold or low fever. In the case of a more severe illness with a fever or any type of infection, wait until you get better before receiving this vaccine.


You should not receive a booster vaccine if you had a life-threatening allergic reaction after the first shot.

Keep track of any and all side effects you have after receiving this vaccine. When you receive a booster dose, you will need to tell the doctor if the previous shots caused any side effects.


Becoming infected with rubella is much more dangerous to your health than receiving the vaccine to protect against these diseases. Like any medicine, this vaccine can cause side effects, but the risk of serious side effects is extremely low.


What should I discuss with my healthcare provider before receiving this vaccine?


You should not receive this vaccine if you are allergic to:

  • gelatin;




  • neomycin (Mycifradin, Neo-Fradin, Neo-Tab); or




  • if you have ever had a life-threatening allergic reaction to any vaccine containing rubella.



You should also not receive this vaccine if you have:



  • a blood cell disorder such as anemia;




  • blood or bone marrow cancer such as leukemia, lymphoma, and others;




  • severe active immune suppression caused by disease (such as cancer, HIV, or AIDS), or by receiving chemotherapy or radiation; or




  • if you are pregnant.



Before receiving this vaccine, tell the doctor if you have:



  • thrombocytopenia purpura (easy bruising or bleeding);




  • active or untreated tuberculosis infection;




  • a weak immune system caused by disease, bone marrow transplant, or by using certain medicines or receiving cancer treatments; or




  • if you have received an immune globulin or other blood product within the past 3 months.



You can still receive a vaccine if you have a minor cold or low fever. In the case of a more severe illness with a fever or any type of infection, wait until you get better before receiving this vaccine.


You should not receive a rubella virus vaccine if you are pregnant. Wait until after your child is born to receive the vaccine. Avoid becoming pregnant for at least 3 months after receiving a rubella virus vaccine. Do not receive this vaccine while you are breast-feeding a baby. Small amounts of the rubella virus contained in the vaccine can pass into breast milk and could harm a nursing baby.

Rubella virus vaccine contains albumin (part of the blood) and it may contain viruses and other infectious agents that can cause disease. Although donated human blood is screened, tested, and treated to reduce the risk of it containing anything that could cause disease, there is still a small possibility it could transmit disease. Talk with your doctor about the risks and benefits of receiving this vaccine.


How is this vaccine given?


This vaccine is given as an injection (shot) under your skin. You will receive this injection in a doctor's office or other clinic setting.


Rubella virus vaccine is recommended for people in the following situations:



  • healthcare workers;




  • college students;




  • military personnel;




  • travelers on cruise ships or to destinations outside the U.S.;




  • a woman who is susceptible to rubella and has just had a baby; and




  • a child who has never been vaccinated against rubella and is in contact with a pregnant woman.



Adults born after 1956 should receive at least one measles, mumps, and rubella (MMR) vaccination if they have never had the diseases or received an MMR vaccine during their lifetime.


The first rubella virus vaccine is usually given to a child who is 12 to 15 month old. The booster shots are then given between 4 and 6 years of age. A measles, mumps, and rubella (MMR) vaccine should then be given before the child starts elementary school.


Your doctor may want you to receive an immune globulin (IG) injection within 3 months after you receive the rubella virus vaccine. Your individual booster schedule may be different from these guidelines. Follow your doctor's instructions or the schedule recommended by the health department of the state you live in.

Your doctor may recommend treating fever and pain with an aspirin-free pain reliever such as acetaminophen (Tylenol) or ibuprofen (Motrin, Advil, and others) when the shot is given and for the next 24 hours. Follow the label directions or your doctor's instructions about how much of this medicine to take.


It is especially important to prevent fever from occurring if you have a seizure disorder such as epilepsy.


This vaccine can cause false results on a skin test for tuberculosis. Tell any doctor who tests you if you have received a rubella virus vaccine within the past 4 to 6 weeks.


What happens if I miss a dose?


Contact your doctor if you will miss a booster dose or if you get behind schedule. The next dose should be given as soon as possible. There is no need to start over.


Be sure you receive all recommended doses of this vaccine. If you do not receive the full series of vaccines, you may not be fully protected against the disease.


What happens if I overdose?


An overdose of this vaccine is unlikely to occur.


What should I avoid before or after receiving this vaccine?


An immune globulin (IG) injection should not be given at the same time as the rubella virus vaccine.


Rubella virus vaccines side effects


You should not receive a booster vaccine if you had a life-threatening allergic reaction after the first shot. Keep track of any and all side effects you have after receiving this vaccine. When you receive a booster dose, you will need to tell the doctor if the previous shots caused any side effects.

Becoming infected with measles, mumps, or rubella is much more dangerous to your health than receiving the vaccine to protect against these diseases. Like any medicine, this vaccine can cause side effects, but the risk of serious side effects is extremely low.


Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have any of these serious side effects:



  • high fever (within a few hours or a few days after the vaccine);




  • swollen glands;




  • easy bruising or bleeding, unusual weakness;




  • joint swelling or stiffness that continues for several weeks after vaccination;




  • weakness, severe lower back pain, numbness or tingly feeling in your feet and spreading upward;




  • problems with hearing, vision, speech, swallowing, or bladder and bowel functions;




  • slow heart rate, trouble breathing, feeling like you might pass out;




  • seizure (black-out or convulsions); or




  • severe blistering, peeling, and red skin rash.



Less serious side effects include:



  • low fever, sore throat, cough, runny nose;




  • headache, dizziness, feeling tired or irritable;




  • nausea, vomiting, diarrhea;




  • joint or muscle pain;




  • numbness or tingly feeling; or




  • redness, pain, swelling, or a lump where the shot was given.



This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report vaccine side effects to the US Department of Health and Human Services at 1-800-822-7967.


Rubella virus vaccine Dosing Information


Usual Adult Dose for Rubella Prophylaxis:

0.5 mL subcutaneously into the outer aspect of the upper arm.

Usual Pediatric Dose for Rubella Prophylaxis:

>= 1 year: 0.5 mL subcutaneously into the outer aspect of the upper arm. Primary vaccination is recommended at age 12 to 15 months.

Revaccination with measles/mumps/rubella vaccine is recommended before entry into elementary school.


What other drugs will affect rubella virus vaccine?


Before receiving this vaccine, tell the doctor about all other vaccines you have recently received.

Also tell the doctor if you have recently received drugs or treatments that can weaken the immune system, including:



  • an oral, nasal, inhaled, or injectable steroid medicine;




  • medications to treat psoriasis, rheumatoid arthritis, or other autoimmune disorders, such as azathioprine (Imuran), efalizumab (Raptiva), etanercept (Enbrel), leflunomide (Arava), and others; or




  • medicines to treat or prevent organ transplant rejection, such as basiliximab (Simulect), cyclosporine (Sandimmune, Neoral, Gengraf), muromonab-CD3 (Orthoclone), mycophenolate mofetil (CellCept), sirolimus (Rapamune), or tacrolimus (Prograf).



If you are using any of these medications, you may not be able to receive the vaccine, or may need to wait until the other treatments are finished.


There may be other drugs that can affect this vaccine. Tell your doctor about all the prescription and over-the-counter medications you have received. This includes vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start using a new medication without telling your doctor.



More rubella virus vaccine resources


  • Rubella virus vaccine Side Effects (in more detail)
  • Rubella virus vaccine Use in Pregnancy & Breastfeeding
  • Rubella virus vaccine Drug Interactions
  • Rubella virus vaccine Support Group
  • 0 Reviews for Rubella virus vaccine - Add your own review/rating


  • Rubella Virus Vaccine MedFacts Consumer Leaflet (Wolters Kluwer)

  • Meruvax II Advanced Consumer (Micromedex) - Includes Dosage Information



Compare rubella virus vaccine with other medications


  • Rubella Prophylaxis


Where can I get more information?


  • Your doctor or pharmacist may have information about this vaccine written for health professionals that you may read. You may also find additional information from your local health department or the Centers for Disease Control and Prevention.

See also: rubella virus vaccine side effects (in more detail)


Monday, 20 July 2009

Gradiab




Gradiab may be available in the countries listed below.


Ingredient matches for Gradiab



Metformin

Metformin hydrochloride (a derivative of Metformin) is reported as an ingredient of Gradiab in the following countries:


  • Indonesia

International Drug Name Search

Friday, 17 July 2009

Ebastina Normon




Ebastina Normon may be available in the countries listed below.


Ingredient matches for Ebastina Normon



Ebastine

Ebastine is reported as an ingredient of Ebastina Normon in the following countries:


  • Spain

International Drug Name Search

Wednesday, 15 July 2009

Portalak




Portalak may be available in the countries listed below.


Ingredient matches for Portalak



Lactulose

Lactulose is reported as an ingredient of Portalak in the following countries:


  • Bosnia & Herzegowina

  • Croatia (Hrvatska)

  • Serbia

  • Slovenia

International Drug Name Search

Wednesday, 8 July 2009

Cytovene


Cytovene is a brand name of ganciclovir, approved by the FDA in the following formulation(s):


CYTOVENE (ganciclovir sodium - injectable; injection)



  • Manufacturer: ROCHE PALO

    Approval date: June 23, 1989

    Strength(s): EQ 500MG BASE/VIAL [RLD][AP]

Has a generic version of Cytovene been approved?


Yes. The following products are equivalent to Cytovene:


GANCICLOVIR (ganciclovir sodium injectable; injection)



  • Manufacturer: APP PHARMS

    Approval date: June 21, 2010

    Strength(s): EQ 500MG BASE/VIAL [AP]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cytovene. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Cytovene.

See also...

  • Cytovene Consumer Information (Wolters Kluwer)
  • Cytovene Capsules Consumer Information (Wolters Kluwer)
  • Cytovene oral and injectable Consumer Information (Cerner Multum)
  • Cytovene Advanced Consumer Information (Micromedex)
  • Cytovene IV Advanced Consumer Information (Micromedex)
  • Cytovene AHFS DI Monographs (ASHP)
  • Ganciclovir Consumer Information (Wolters Kluwer)
  • Ganciclovir Capsules Consumer Information (Wolters Kluwer)
  • Ganciclovir oral and injectable Consumer Information (Cerner Multum)
  • Ganciclovir Oral, Intravenous Advanced Consumer Information (Micromedex)
  • Ganciclovir Sodium AHFS DI Monographs (ASHP)

Thursday, 25 June 2009

TNKase




In the US, TNKase (tenecteplase systemic) is a member of the drug class thrombolytics and is used to treat Heart Attack.

US matches:

  • TNKase

Ingredient matches for TNKase



Tenecteplase

Tenecteplase is reported as an ingredient of TNKase in the following countries:


  • Canada

  • United States

International Drug Name Search

Acerycal




Acerycal may be available in the countries listed below.


Ingredient matches for Acerycal



Amlodipine

Amlodipine is reported as an ingredient of Acerycal in the following countries:


  • Ireland

Perindopril

Perindopril arginine (a derivative of Perindopril) is reported as an ingredient of Acerycal in the following countries:


  • Ireland

International Drug Name Search

Tuesday, 23 June 2009

Cyprofloksacyna




Cyprofloksacyna may be available in the countries listed below.


Ingredient matches for Cyprofloksacyna



Ciprofloxacin

Ciprofloxacin is reported as an ingredient of Cyprofloksacyna in the following countries:


  • Poland

International Drug Name Search

Plastranit




Plastranit may be available in the countries listed below.


Ingredient matches for Plastranit



Nitroglycerin

Nitroglycerin is reported as an ingredient of Plastranit in the following countries:


  • Portugal

International Drug Name Search

Sunday, 21 June 2009

Venectomin




Venectomin may be available in the countries listed below.


Ingredient matches for Venectomin



Potassium Canrenoate

Potassium Canrenoate is reported as an ingredient of Venectomin in the following countries:


  • Japan

International Drug Name Search

Wednesday, 3 June 2009

Dicynone




Dicynone may be available in the countries listed below.


Ingredient matches for Dicynone



Etamsylate

Etamsylate is reported as an ingredient of Dicynone in the following countries:


  • Bahrain

  • Belgium

  • Bosnia & Herzegowina

  • Bulgaria

  • Colombia

  • Croatia (Hrvatska)

  • Czech Republic

  • France

  • Georgia

  • Hungary

  • Indonesia

  • Italy

  • Latvia

  • Lithuania

  • Luxembourg

  • Malta

  • Mexico

  • Oman

  • Peru

  • Romania

  • Russian Federation

  • Serbia

  • Singapore

  • Slovakia

  • Switzerland

  • Tunisia

  • Venezuela

International Drug Name Search

Monday, 25 May 2009

Bisacodyl Uniserts




In the US, Bisacodyl Uniserts is a member of the drug class laxatives and is used to treat Bowel Preparation and Constipation.

Ingredient matches for Bisacodyl Uniserts



Bisacodyl

Bisacodyl is reported as an ingredient of Bisacodyl Uniserts in the following countries:


  • United States

International Drug Name Search

Monday, 18 May 2009

Enrocin




Enrocin may be available in the countries listed below.


In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Enrocin



Enrofloxacin

Enrofloxacin is reported as an ingredient of Enrocin in the following countries:


  • Poland

International Drug Name Search

Sunday, 17 May 2009

Kafosed




Kafosed may be available in the countries listed below.


Ingredient matches for Kafosed



Dextromethorphan

Dextromethorphan hydrobromide (a derivative of Dextromethorphan) is reported as an ingredient of Kafosed in the following countries:


  • Bahrain

  • Oman

International Drug Name Search

Spironolacton Sandoz




Spironolacton Sandoz may be available in the countries listed below.


Ingredient matches for Spironolacton Sandoz



Spironolactone

Spironolactone is reported as an ingredient of Spironolacton Sandoz in the following countries:


  • Germany

  • Netherlands

International Drug Name Search

Saturday, 16 May 2009

Bisacardiol




Bisacardiol may be available in the countries listed below.


Ingredient matches for Bisacardiol



Bisoprolol

Bisoprolol fumarate (a derivative of Bisoprolol) is reported as an ingredient of Bisacardiol in the following countries:


  • Austria

International Drug Name Search

Thursday, 14 May 2009

Arcatamin




Arcatamin may be available in the countries listed below.


Ingredient matches for Arcatamin



Sulbutiamine

Sulbutiamine is reported as an ingredient of Arcatamin in the following countries:


  • Vietnam

International Drug Name Search

Monday, 11 May 2009

Pyorex




Pyorex may be available in the countries listed below.


Ingredient matches for Pyorex



Ethacridine

Ethacridine is reported as an ingredient of Pyorex in the following countries:


  • Tunisia

International Drug Name Search

Saturday, 9 May 2009

Permiltin




Permiltin may be available in the countries listed below.


Ingredient matches for Permiltin



Dipyridamole

Dipyridamole is reported as an ingredient of Permiltin in the following countries:


  • Japan

International Drug Name Search

Saturday, 2 May 2009

Nausea




Nausea may be available in the countries listed below.


Ingredient matches for Nausea



Domperidone

Domperidone is reported as an ingredient of Nausea in the following countries:


  • Japan

International Drug Name Search

Saturday, 25 April 2009

Lergy




Lergy may be available in the countries listed below.


Ingredient matches for Lergy



Cetirizine

Cetirizine dihydrochloride (a derivative of Cetirizine) is reported as an ingredient of Lergy in the following countries:


  • Turkey

International Drug Name Search

Sunday, 19 April 2009

Best Friend Hundehalsband




Best Friend Hundehalsband may be available in the countries listed below.


In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Best Friend Hundehalsband



Dimpylate

Dimpylate is reported as an ingredient of Best Friend Hundehalsband in the following countries:


  • Switzerland

International Drug Name Search

Friday, 17 April 2009

Adspec




In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Adspec



Spectinomycin

Spectinomycin is reported as an ingredient of Adspec in the following countries:


  • United States

International Drug Name Search

Thursday, 16 April 2009

Sopira Citocartin mit Epinephrin




Sopira Citocartin mit Epinephrin may be available in the countries listed below.


Ingredient matches for Sopira Citocartin mit Epinephrin



Articaine

Articaine hydrochloride (a derivative of Articaine) is reported as an ingredient of Sopira Citocartin mit Epinephrin in the following countries:


  • Germany

Epinephrine

Epinephrine bitartrate (a derivative of Epinephrine) is reported as an ingredient of Sopira Citocartin mit Epinephrin in the following countries:


  • Germany

International Drug Name Search

Friday, 10 April 2009

Bestaferon




Bestaferon may be available in the countries listed below.


Ingredient matches for Bestaferon



Interferon beta

Interferon beta Interferon beta-1b (a derivative of Interferon beta) is reported as an ingredient of Bestaferon in the following countries:


  • Mexico

International Drug Name Search

Thursday, 2 April 2009

Fenspiride




Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

R03BX01,R03DX03

CAS registry number (Chemical Abstracts Service)

0005053-06-5

Chemical Formula

C15-H20-N2-O2

Molecular Weight

260

Therapeutic Categories

Anti-inflammatory agent

Bronchodilator

Chemical Name

1-Oxa-3,8-diazaspiro[4.5]decan-2-one, 8-(2-phenylethyl)-

Foreign Names

  • Fenspiridum (Latin)
  • Fenspirid (German)
  • Fenspiride (French)
  • Fenspirida (Spanish)

Generic Names

  • Fenspiride (OS: DCIT, DCF)
  • Decaspiride (IS)
  • DESP (IS)
  • JP 428 (IS)
  • Fenspiride Hydrochloride (OS: USAN)
  • NAT-333 (IS)
  • NDR-5998-A (IS)
  • S 3612 (IS)

Brand Names

  • Eurespal
    Servier, Poland; Servier, Romania; Servier, Russian Federation; Servier, Bulgaria


  • Fenspiride
    Pei Li, Taiwan


  • Pneumorel
    Euthérapie, France; Servier, Portugal; Servier, Vietnam; Servier-F, Italy


  • Pulneo
    Aflofarm, Poland

International Drug Name Search

Glossary

DCFDénomination Commune Française
DCITDenominazione Comune Italiana
ISInofficial Synonym
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Thursday, 19 March 2009

Levomenthol




In some countries, this medicine may only be approved for veterinary use.

Scheme

Rec.INN

CAS registry number (Chemical Abstracts Service)

0002216-51-5

Chemical Formula

C10-H20-O

Molecular Weight

156

Therapeutic Category

Antipruritic

Chemical Name

(-)-(1R,3R,4S)-Menthol

Foreign Names

  • Levomentholum (Latin)
  • Levomenthol (German)
  • Lévomenthol (French)
  • Levomentol (Spanish)

Generic Names

  • Levomenthol (OS: BAN)
  • l-Menthol (OS: JAN)
  • Menthol (OS: DCF)
  • Levomenthol (PH: BP 2010, Ph. Eur. 6)
  • Lévomenthol (PH: Ph. Eur. 6)
  • Levomentholum (PH: Ph. Eur. 6)
  • Menthol (PH: USP 32)

Brand Names

  • Balsamorhinol (Levomenthol and Chlorobutanol)
    Pierre Fabre Médicament, France


  • Cliptol (Levomenthol and Ibuprofen)
    Pierre Fabre Médicament, France


  • Coryfin (Levomenthol and Ascorbic Acid)
    SIT, Italy


  • Deep Relief (Levomenthol and Ibuprofen)
    Oktal, Croatia (Hrvatska)


  • Dentobaume (Levomenthol and Amylocaine)
    Tradiphar, France


  • Dip Rilif (Levomenthol and Ibuprofen)
    Mentholatum, Poland


  • Fisherman's Friend Cinnamon
    Uhlmann-Eyraud Pharma, Switzerland


  • Fisherman's Friend Lemon
    Uhlmann-Eyraud Pharma, Switzerland


  • Levomenthol / Methylsalicylaat (Levomenthol and Methyl Salicylate)
    ratiopharm, Netherlands


  • Mentolo Afom Medical
    AFOM, Italy


  • Mentolo Alvita
    Alvita, Italy


  • Mentolo Farmacologico
    Farmacologico, Italy


  • Mentolo Giovanardi
    Giovanardi, Italy


  • Mentolo Marco Viti
    Marco Viti, Italy


  • Mentolo Nova Argentia
    Nova Argentia, Italy


  • Mentolo Ramini
    Ramini, Italy


  • Mentolo Sella
    Sella, Italy


  • Mentolo Zeto
    Zeta, Italy


  • Menturm Q (Levomenthol and Methyl Salicylate)
    OMI, Japan


  • Perskindol
    Vifor, Switzerland


  • Pinimenthol
    Piniol, Switzerland


  • Radolin (Levomenthol and D-Camphor (veterinary use))
    Streuli Vet, Switzerland


  • Reumatol (Levomenthol and Methyl Salicylate)
    Gemi, Poland


  • Robitussin Honey Cough
    Wyeth Consumer Healthcare, New Zealand


  • Tekuty Puder (Levomenthol and Zinc Oxide)
    Galvex, Slovakia


  • Vicks Formula 44 (Levomenthol and Dextromethorphan)
    Procter & Gamble, New Zealand


  • Vicks Inhaler N (Levomenthol and Camphor)
    Procter & Gamble, Switzerland


  • Wick Inhalierstift (Levomenthol and Camphor)
    Wick, Germany


  • Wick-Inhalierstift
    Procter & Gamble, Austria


  • Wintogeno (Levomenthol and Methyl salicylate)
    Actavis, Indonesia

International Drug Name Search

Glossary

BANBritish Approved Name
DCFDénomination Commune Française
JANJapanese Accepted Name
OSOfficial Synonym
PHPharmacopoeia Name
Rec.INNRecommended International Nonproprietary Name (World Health Organization)

Click for further information on drug naming conventions and International Nonproprietary Names.

Tuesday, 17 March 2009

Penicillin G Actavis




Penicillin G Actavis may be available in the countries listed below.


Ingredient matches for Penicillin G Actavis



Benzylpenicillin

Benzylpenicillin is reported as an ingredient of Penicillin G Actavis in the following countries:


  • Latvia

Benzylpenicillin sodium (a derivative of Benzylpenicillin) is reported as an ingredient of Penicillin G Actavis in the following countries:


  • Estonia

  • Lithuania

International Drug Name Search

Monday, 16 March 2009

Clopigamma




Clopigamma may be available in the countries listed below.


Ingredient matches for Clopigamma



Clopidogrel

Clopidogrel besilate (a derivative of Clopidogrel) is reported as an ingredient of Clopigamma in the following countries:


  • Germany

International Drug Name Search

Thursday, 12 March 2009

Viridin




Viridin may be available in the countries listed below.


Ingredient matches for Viridin



Trifluridine

Trifluridine is reported as an ingredient of Viridin in the following countries:


  • Portugal

International Drug Name Search

Wednesday, 11 March 2009

Diphenhydramine Cream



Pronunciation: DYE-fen-HYE-dra-meen
Generic Name: Diphenhydramine
Brand Name: Examples include Benadryl and Dermarest


Diphenhydramine Cream is used for:

Temporarily relieving pain and itching associated with insect bites, minor burns, sunburn, minor skin irritations, minor cuts, scrapes, and rashes caused by poison ivy, poison oak, and poison sumac.


Diphenhydramine Cream is an antihistamine. It works by blocking the action of histamine, which reduces the symptoms of an allergic reaction.


Do NOT use Diphenhydramine Cream if:


  • you are allergic to any ingredient in Diphenhydramine Cream

  • you use any other medicine that contains diphenhydramine, unless your doctor tells you to

Contact your doctor or health care provider right away if any of these apply to you.



Before using Diphenhydramine Cream:


Some medical conditions may interact with Diphenhydramine Cream. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, planning to become pregnant, or are breast-feeding

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines, foods, or other substances

  • if you have porphyria

Some MEDICINES MAY INTERACT with Diphenhydramine Cream. Because little, if any, of Diphenhydramine Cream is absorbed into the blood, the risk of it interacting with another medicine is low.


Ask your health care provider if Diphenhydramine Cream may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Diphenhydramine Cream:


Use Diphenhydramine Cream as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • Diphenhydramine Cream is for external use only. Avoid contact with the eyes. Do not swallow Diphenhydramine Cream.

  • Wash and completely dry the affected area. Gently rub the medicine in until it is evenly distributed. Apply to the affected area not more than 3 to 4 times a day.

  • Wash your hands immediately after using Diphenhydramine Cream.

  • If you miss a dose of Diphenhydramine Cream and you are using it regularly, use it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule.

Ask your health care provider any questions you may have about how to use Diphenhydramine Cream.



Important safety information:


  • Diphenhydramine Cream may cause harm if it is swallowed. If you have taken it by mouth, contact your poison control center or emergency room right away.

  • If your symptoms do not get better within 7 days, if they get worse, or if they come back, stop using Diphenhydramine Cream and check with your doctor.

  • Do not use on chickenpox, measles, or on large areas of the body, including large areas of poison ivy, sunburn, or broken, blistered, or oozing skin, unless advised to do so by your doctor.

  • Diphenhydramine Cream has diphenhydramine in it. Before you start any new medicine, including one used on the skin, check the label to see if it has diphenhydramine in it too. If it does or if you are not sure, check with your doctor or pharmacist.

  • Diphenhydramine Cream should not be used in CHILDREN younger than 2 years old; safety and effectiveness in these children have not been confirmed.

  • PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Diphenhydramine Cream while you are pregnant. Diphenhydramine Cream is found in breast milk. If you are or will be breast-feeding while you use Diphenhydramine Cream, check with your doctor. Discuss any possible risks to your baby.


Possible side effects of Diphenhydramine Cream:


All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:



Skin irritation.



Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue).



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.



If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Diphenhydramine Cream may be harmful if swallowed. Symptoms after swallowing Diphenhydramine Cream may include confusion, hallucinations, or loss of consciousness.


Proper storage of Diphenhydramine Cream:

Store Diphenhydramine Cream at room temperature, between 59 and 77 degrees F (15 and 25 degrees C). Store away from heat, moisture, and light. Keep Diphenhydramine Cream out of the reach of children and away from pets.


General information:


  • If you have any questions about Diphenhydramine Cream, please talk with your doctor, pharmacist, or other health care provider.

  • Diphenhydramine Cream is to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

  • Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Diphenhydramine Cream. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Diphenhydramine resources


  • Diphenhydramine Use in Pregnancy & Breastfeeding
  • Diphenhydramine Drug Interactions
  • Diphenhydramine Support Group
  • 0 Reviews for Diphenhydramine - Add your own review/rating


Compare Diphenhydramine with other medications


  • Pain
  • Pruritus

Oftalmol




Oftalmol may be available in the countries listed below.


Ingredient matches for Oftalmol



Prednisolone

Prednisolone is reported as an ingredient of Oftalmol in the following countries:


  • Serbia

International Drug Name Search

Saturday, 7 March 2009

Recain




Recain may be available in the countries listed below.


Ingredient matches for Recain



Bupivacaine

Bupivacaine is reported as an ingredient of Recain in the following countries:


  • Indonesia

International Drug Name Search

Tuesday, 24 February 2009

Olanzapin Hexal




Olanzapin Hexal may be available in the countries listed below.


Ingredient matches for Olanzapin Hexal



Olanzapine

Olanzapine is reported as an ingredient of Olanzapin Hexal in the following countries:


  • Germany

  • Luxembourg

International Drug Name Search

Thursday, 19 February 2009

Penstapho-N




Penstapho-N may be available in the countries listed below.


Ingredient matches for Penstapho-N



Cloxacillin

Cloxacillin sodium salt (a derivative of Cloxacillin) is reported as an ingredient of Penstapho-N in the following countries:


  • Luxembourg

International Drug Name Search

Aspercreme




In the US, Aspercreme (trolamine salicylate topical) is a member of the drug class miscellaneous topical agents and is used to treat Back Pain, Bursitis, Osteoarthritis, Pain, Period Pain, Raynaud's Syndrome, Rheumatoid Arthritis and Tendonitis.

US matches:

  • Aspercreme Cream

Ingredient matches for Aspercreme



Trolamine

Trolamine salicylate (a derivative of Trolamine) is reported as an ingredient of Aspercreme in the following countries:


  • United States

International Drug Name Search

Sunday, 1 February 2009

Disulfiram


Class: Alcohol Deterrents
ATC Class: N07BB01
VA Class: AD100
CAS Number: 97-77-8
Brands: Antabuse



  • Never administer to a patient in a state of alcohol intoxication or without patient's full knowledge; instruct relatives accordingly.a b




Introduction

Alcohol deterrent; an aldehyde dehydrogenase inhibitor.a b


Uses for Disulfiram


Alcohol Dependence


Management of alcohol dependence in selected, highly motivated patients; use in conjunction with supportive and psychotherapeutic treatment.a b


Not a cure for alcohol dependence; unlikely to have substantive effect when used without proper motivation and supportive therapy.b


Disulfiram Dosage and Administration


General



  • Initiate therapy in a hospital or physician’s office after a complete physical examination.a




  • Patient must be fully aware of therapy, thoroughly understand the disulfiram-alcohol reaction, and be supervised by regular office visits and psychotherapy.a b



Disulfiram-Alcohol Test Reaction



  • Considered by most clinicians to be unnecessary and may be associated with increased drug toxicity.a




  • If deemed necessary, perform only under careful medical supervision (e.g., in a hospital) and with adequate facilities (including oxygen) available for treatment of a severe reaction.a b Do not perform test reaction in patients >50 years of age.a b




  • After 1–2 weeks of disulfiram therapy, slowly administer 15 mL of 100-proof whiskey (or its equivalent) to the patient; dose of alcohol may be repeated once but should not exceed 30 mL of whiskey.a b Discontinue alcohol as soon as symptoms develop.a b (See Disulfiram-Alcohol Reaction under Cautions.)



Adherence to Therapy



  • Assume patients on maintenance doses who report ability to drink alcoholic beverages without symptoms are disposing of disulfiram tablets without ingesting.b Observe daily intake of tablets (preferably crushed and well mixed with liquid) before concluding disulfiram is ineffective.b



Administration


Oral Administration


Administer orally once daily, usually in the morning.b If sedation occurs, may administer at bedtime.b


Do not administer until patient has abstained from alcohol for ≥12 hours.b Never administer without the patient’s knowledge.b (See Boxed Warning.)


If adherence is a problem, administer under close supervision, preferably as crushed tablets well mixed with liquid.a b


Dosage


Adults


Alcohol Dependence

Oral

Initially, maximum 500 mg once daily for 1–2 weeks.a b May reduce dosage if sedation occurs.b


Average maintenance dosage: 250 mg daily (range: 125–500 mg daily) until patient is fully recovered socially and a basis for permanent self-control is established.a b Treatment may be required for months or years.a b


Prescribing Limits


Adults


Alcohol Dependence

Oral

Maximum 500 mg daily.a b


Special Populations


Hepatic Impairment


No specific dosage recommendations at this time.a b Use with extreme caution.b (See Hepatic Effects and also Concomitant Diseases under Cautions.)


Renal Impairment


No specific dosage recommendations at this time.a b Use with extreme caution in patients with acute or chronic nephritis.b (See Concomitant Diseases under Cautions.)


Geriatric Patients


Select dosage with caution, usually starting at low end of dosing range, because of age-related decreases in hepatic, renal, and/or cardiac function and of concomitant disease and drug therapy.b


Cautions for Disulfiram


Contraindications



  • Concurrent or recent use of metronidazole, paraldehyde (no longer commercially available in the US), alcohol, or alcohol-containing preparations (e.g., cough syrups, elixirs, tonics).a b (See Disulfiram-Alcohol Reaction under Cautions and also see Advice to Patients.)




  • Alcohol intoxication.a b




  • Severe myocardial disease, coronary occlusion, or psychoses.a b




  • Hypersensitivity to disulfiram or to other thiuram derivatives used in pesticides and rubber vulcanization.a b



Warnings/Precautions


Warnings


Disulfiram-Alcohol Reaction

Ingestion of alcohol (even small amounts) produces an adverse disulfiram-alcohol reaction.a b Symptoms include: flushing, throbbing in the head and neck, throbbing headache, respiratory difficulty, dyspnea, nausea, copious vomiting, sweating, thirst, chest pain, palpitation, hyperventilation, tachycardia, hypotension, syncope, marked uneasiness, anxiety, weakness, vertigo, blurred vision, and confusion.a b Mild reactions are usually followed by sound sleep and complete recovery.a May progress to respiratory depression, cardiovascular collapse, arrhythmias, MI, acute CHF, unconsciousness, seizures, and death.a b


Reaction may last 30–60 minutes to several hours or as long as alcohol remains in the blood.a b Intensity and duration of the reaction are subject to individual variation and are proportional to the dosage of both disulfiram and alcohol; a blood alcohol concentration (BAC) of 5–10 mg/dL may precipitate a reaction.a b Symptoms are fully developed when BAC=50 mg/dL; unconsciousness generally occurs when BAC ≥125–150 mg/dL.a b Most fatal reactions occur with disulfiram dosages >500 mg daily and >2 alcoholic drinks; however, deaths have occurred with lower disulfiram dosages after a single alcoholic drink (approximately 150 mg/kg of ethanol).a


Treatment of disulfiram-alcohol reaction should be performed in facilities with immediate access to emergency equipment and drugs (e.g., emergency rooms) since arrhythmias and severe hypotension occasionally occur.a Institute supportive measures to restore BP and treat shock (e.g., oxygen or a mixture of 95% oxygen and 5% carbon dioxide, plasma or electrolyte solutions, ephedrine sulfate).a b Large IV doses of ascorbic acid (1 g), iron,b and antihistamines have been used, but are of questionable value.a The therapeutic role of prostaglandin synthetase inhibitors (e.g., indomethacin) and histamine H2-blocking agents (e.g., cimetidine) in decreasing the flushing reaction has not been established.a Because hypokalemia has been reported, monitor serum potassium concentrations, particularly in digitalized patients.a b


Fully inform patients about the disulfiram-alcohol reaction.b Warn against surreptitious drinking and/or use of alcohol-containing products and advise of possible consequences.b (See Advice to Patients.) Advise patients to carry a disulfiram identification card listing symptoms of the disulfiram-alcohol reaction and clinician contact information.b Cards may be obtained from Odyssey Pharmaceuticals at 1-877-427-9068.b


Concomitant Diseases

Because of risk of accidental disulfiram-alcohol reaction, use with extreme caution in patients with diabetes mellitus, hypothyroidism, seizure disorders, cerebral damage, chronic or acute nephritis, hepatic cirrhosis or insufficiency, abnormal EEG results, or multiple drug dependence.a b


Sensitivity Reactions


Evaluate patients with a history of rubber contact dermatitis for hypersensitivity to thiuram derivatives before beginning disulfiram.a b (See Contraindications under Cautions.)


Major Toxicities


Hepatic Effects

Hepatic toxicity (e.g., cholestatic or fulminant hepatitis, hepatic failure resulting in transplantation or death) reported in patients with or without prior history of abnormal liver function.104 b Severe or fatal hepatitis may develop even after many months of therapy.103


Perform baseline and follow-up liver function tests every 10–14 days; monitor CBC and blood chemistries.104 Advise patients to immediately report early signs or symptoms of hepatitis.104 (See Advice to Patients.)


Nervous System Effects

Vertigo, irritability, insomnia, abnormal gait, slurred speech, disorientation, confusion, and personality changes reported.a Tonic-clonic (grand mal) seizures, peripheral neuropathy, polyneuritis, optic neuritis, delirium, bizarre behavior, drowsiness, and psychoses also reported.a


Possible exacerbation of preexisting EEG abnormalities.a


General Precautions


Precipitation of New Abuse

Alcoholism may accompany or be followed by dependence on narcotics or sedatives; consider possibility of precipitating a new abuse.b


Ethylene Dibromide Exposure

Do not expose patients on disulfiram to ethylene dibromide or its vapors; higher incidence of tumors and mortality observed in rats.a b


Specific Populations


Pregnancy

Category C.c


Lactation

Not known whether disulfiram is distributed into milk;b however, expected to distribute into milk because of relatively low molecular weight.c Use not recommended.b


Pediatric Use

Safety and efficacy not established.b


Geriatric Use

Response in patients ≥65 years of age does not appear to differ from that in younger adults.b However, select dosage with caution because of greater frequency of decreased hepatic, renal, and/or cardiac function and of concomitant disease and drug therapy observed in the elderly.b (See Geriatric Patients under Dosage and Administration.)


Hepatic Impairment

Use with extreme caution.b (See Hepatic Effects and also Concomitant Diseases under Cautions.)


Renal Impairment

Use with extreme caution in patients with chronic or acute nephritis.b (See Concomitant Diseases under Cautions.)


Common Adverse Effects


Cholestatic or fulminant hepatitis, hepatic failure, skin eruptions (e.g., acneiform eruptions, allergic dermatitis), drowsiness, fatigue, impotence, headache, metallic or garlic-like aftertaste, psychotic reactions.b Optic or peripheral neuritis, polyneuritis, or peripheral neuropathy also may occur.b


Interactions for Disulfiram


Nonspecific inhibitor of microsomal drug metabolism.a


Specific Drugs






























Drug



Interaction



Comments



Alcohol or alcohol-containing preparations (e.g., cough syrups, elixirs, tonics)



Increased sensitivity to alcohol, resulting in disulfiram-alcohol reactionb



Concomitant use contraindicatedb



Amitriptyline



Enhanced alcohol-disulfiram reactiona



Anticoagulants, oral (e.g., warfarin)



Possible increased plasma concentrations of anticoagulant, resulting in prolonged PT105 b



Adjust anticoagulant dosage as needed upon initiation or discontinuance of disulfiram105 b



Barbiturates



Interference with hepatic metabolism of barbiturate, possibly resulting in increased blood concentrations and toxicity of barbituratea



Caffeine



Decreased total blood clearance and increased half-life of caffeine, possibly resulting from inhibition of hepatic metabolism of caffeine100



Clinical importance not established, but consider possibility of exaggerated or prolonged caffeine effects in patients who ingest substantial quantities of coffee, tea, or other caffeine-containing beverages100 101



Isoniazid



Possible behavioral changes, marked changes in mental status, psychotic reactions, incoordination, or unsteady gaita b



Avoid concomitant use.a However, if used concomitantly, discontinue disulfiram if such signs appearb



Metronidazole



Acute psychoses and confusion reporteda



Concomitant use contraindicateda b



Phenytoin (and congeners)



Inhibition of hepatic metabolism of phenytoin, possibly resulting in phenytoin intoxication103



Use concomitantly with caution.a b Determine phenytoin concentrations prior to and during disulfiram therapy; adjust phenytoin dosage as needed103


Disulfiram Pharmacokinetics


Absorption


Bioavailability


Slowly absorbed from the GI tract.b


Onset


3–12 hours following administration.a


Duration


Effects may persist up to 14 days after last dose.a b


Distribution


Extent


Not known whether disulfiram crosses the placenta or is distributed into milk;b c however, expected to cross the placenta and distribute into milk because of relatively low molecular weight.c


Elimination


Metabolism


Slowly metabolized in the liver to diethyldithiocarbamate, diethylamine, and carbon disulfide.a


Elimination Route


Slowly eliminated from the body.b Excreted principally in urine as metabolites; unabsorbed disulfiram (5–20%) is excreted unchanged in feces.a Some excreted from the lungs as carbon disulfide.a


Stability


Storage


Oral


Tablets

Tight, light-resistant containers at 20–25°C.b


ActionsActions



  • Produces hypersensitivity to alcohol; irreversibly inhibits the enzymatic oxidation of acetaldehyde to acetate, which occurs in the liver during normal alcohol catabolism.a b




  • When small amounts of alcohol are ingested after administration of disulfiram, the acetaldehyde concentration in blood may increase 5–10 times the concentration found during metabolism of the same amount of alcohol alone.a b




  • Unpleasant symptoms of the disulfiram-alcohol reaction probably caused by high blood concentrations of acetaldehyde,b or possibly from formation of a toxic quaternary ammonium compound or carbon disulfide metabolite of disulfiram.a (See Disulfiram-Alcohol Reaction under Cautions.)




  • Does not interfere with rate of alcohol elimination from the body.a b




  • Tolerance does not occur; increased sensitivity to alcohol following prolonged administration.a b



Advice to Patients



  • Importance of understanding that disulfiram is not a cure for alcoholism and must be combined with other treatments.a b




  • Importance that relatives understand never to administer disulfiram to a patient in a state of alcohol intoxication or without his full knowledge.a b




  • Importance of full knowledge and understanding of the disulfiram-alcohol reaction.b Avoid surreptitious drinking and/or use of alcohol in all forms, including disguised forms (e.g., cough syrups, elixirs, tonics, sauces, vinegars, cider, extracts, mouthwashes, aftershave lotions, back rubs).b d Always check list of ingredients before drinking, eating, applying, or inhaling any product; if uncertain about the alcohol content of any product, contact manufacturer before using.d Importance of understanding that disulfiram-alcohol reaction may occur up to 14 days after discontinuance of disulfiram.b




  • Importance of understanding that sensitivity to alcohol increases with prolonged administration.b




  • Importance of obtaining and carrying a disulfiram identification card listing symptoms of the disulfiram-alcohol reaction and emergency clinician contact information.b




  • Importance of immediately informing clinicians of any early signs or symptoms of hepatitis (e.g., fatigue, weakness, malaise, anorexia, nausea, vomiting, jaundice, dark urine).104




  • Importance of informing clinicians of any allergy to pesticides or rubber products.b




  • Importance of informing clinicians of existing or contemplated therapy, including prescription and OTC drugs and dietary or herbal supplements, as well as any concomitant illnesses.b




  • Importance of women informing their clinician if they are or plan to become pregnant or plan to breast-feed.b




  • Importance of informing patients of other important precautionary information.b (See Cautions.)



Preparations


Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.


















Disulfiram

Routes



Dosage Forms



Strengths



Brand Names



Manufacturer



Oral



Tablets



250 mg



Antabuse



Odyssey



500 mg



Antabuse (scored)



Odyssey


Comparative Pricing


This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 03/2011. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.


Antabuse 250MG Tablets (TEVA PHARMACEUTICALS USA): 30/$122.98 or 90/$340.74



Disclaimer

This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.


The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.

AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions February 2009. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.




References


Only references cited for selected revisions after 1984 are available electronically.



100. Beach CA, Mays DC, Guiler RC et al. Inhibition of elimination of caffeine by disulfiram in normal subjects and recovering alcoholics. Clin Pharmacol Ther. 1986; 39:265-70. [IDIS 213983] [PubMed 3948467]



101. Mangini RJ, ed. Drug interaction facts. St. Louis: JB Lippincott Co; 1986(Jul):123a.



102. Anon. Safety of terfenadine and astemizole. Med Lett Drugs Ther. 1992; 34:9-10. [PubMed 1732711]



103. Odyssey pharmaceuticals, Inc. Antabuse (disulfiram, USP) tablets prescribing information. East Hanover, NJ; (undated).



104. Wyeth Laboratories. Antabuse (disulfiram) tablets prescribing information. Philadelphia, PA; 2000 May 22.



105. O’Reilly RA. Interaction of sodium warfarin and disulfiram (Antabuse) in man. Ann Intern Med. 1973; 78:73-6. [PubMed 4682311]



a. AHFS drug information 2007. McEvoy GK, ed. Disulfiram. Bethesda, MD: American Society of Health-System Pharmacists; 2007:3653-4.



b. Odyssey Pharmaceuticals, Inc. Antabuse(disulfiram) tablets prescribing information. East Hanover, NJ; 2003 Dec.



c. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation, 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005:501-2.



d. Odyssey Pharmaceuticals, Inc. What you should know about Antabuse (disulfiram, USP) tablets: Important information for patients taking Antabuse and those who care for them. East Hanover, NJ; undated.



More Disulfiram resources


  • Disulfiram Side Effects (in more detail)
  • Disulfiram Dosage
  • Disulfiram Use in Pregnancy & Breastfeeding
  • Drug Images
  • Disulfiram Drug Interactions
  • Disulfiram Support Group
  • 18 Reviews for Disulfiram - Add your own review/rating


  • Disulfiram Prescribing Information (FDA)

  • Disulfiram MedFacts Consumer Leaflet (Wolters Kluwer)

  • Disulfiram Professional Patient Advice (Wolters Kluwer)

  • disulfiram Advanced Consumer (Micromedex) - Includes Dosage Information

  • Antabuse Consumer Overview

  • Antabuse Prescribing Information (FDA)



Compare Disulfiram with other medications


  • Alcohol Dependence